Synthesis and Biological Evaluation of Tetrahydropyrimidine and Dihydropyridine Derivatives Against Leishmania Major
© 2021. Witold Stefański Institute of Parasitology, Polish Academy of Sciences..
PURPOSE: A number of tetrahydropyrimidines and their bioisosteric dihydropyridines bearing chloro substituent at various positions of phenyl ring in C4 of main scaffolds were designed, synthesized and evaluated for antileishmanial activity.
METHODS: The antileishmanial activity of the synthesized compounds was evaluated against promastigote and amastigote forms. Moreover, molecular docking studies of the compounds in pteridine reductase 1 (PTR1) pocket were carried out to describe the results of biological experiments.
RESULTS: The compounds exhibited moderate to good antileishmanial activity against promastigote and amastigote forms. Among the screened compounds, 1d and 2c were found as the most potent compounds against promastigote form with EC50 values of 15.5 and 10.5 µM, respectively. Compounds 2a and 2c were the most potent compounds against amastigote form with EC50 values of 5.4 and 2.2 µM, respectively.
CONCLUSION: According to structure-activity relationship (SAR) studies, the chloro substituent in different positions of phenyl ring at C4 of 1,2,3,4-tetrahydropyrimidine (THPM) and 1,4-dihydropyridine (DHP) rings and also the length of the chain belonging to the ester groups could be important for antileishmanial activity of these compounds. Most of these compounds exhibited low cytotoxicity against macrophages. Compounds 1 h, 2a, 2b and 2c revealed higher activity than glucantime while all compounds showed lower activity toward amphotericine B. Docking studies showed that the synthesized compounds were fit well in the PTR1 pocket. Compounds 1 h and 2c indicated the highest score docking among screened compounds in PTR1 enzyme.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Acta parasitologica - 67(2022), 1 vom: 19. März, Seite 255-266 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jeddi, Behnaz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amastigotes |
|---|
| Anmerkungen: |
Date Completed 23.03.2022 Date Revised 23.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11686-021-00457-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328251097 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328251097 | ||
| 003 | DE-627 | ||
| 005 | 20231225202548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11686-021-00457-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1094.xml |
| 035 | |a (DE-627)NLM328251097 | ||
| 035 | |a (NLM)34279776 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jeddi, Behnaz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis and Biological Evaluation of Tetrahydropyrimidine and Dihydropyridine Derivatives Against Leishmania Major |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.03.2022 | ||
| 500 | |a Date Revised 23.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. Witold Stefański Institute of Parasitology, Polish Academy of Sciences. | ||
| 520 | |a PURPOSE: A number of tetrahydropyrimidines and their bioisosteric dihydropyridines bearing chloro substituent at various positions of phenyl ring in C4 of main scaffolds were designed, synthesized and evaluated for antileishmanial activity | ||
| 520 | |a METHODS: The antileishmanial activity of the synthesized compounds was evaluated against promastigote and amastigote forms. Moreover, molecular docking studies of the compounds in pteridine reductase 1 (PTR1) pocket were carried out to describe the results of biological experiments | ||
| 520 | |a RESULTS: The compounds exhibited moderate to good antileishmanial activity against promastigote and amastigote forms. Among the screened compounds, 1d and 2c were found as the most potent compounds against promastigote form with EC50 values of 15.5 and 10.5 µM, respectively. Compounds 2a and 2c were the most potent compounds against amastigote form with EC50 values of 5.4 and 2.2 µM, respectively | ||
| 520 | |a CONCLUSION: According to structure-activity relationship (SAR) studies, the chloro substituent in different positions of phenyl ring at C4 of 1,2,3,4-tetrahydropyrimidine (THPM) and 1,4-dihydropyridine (DHP) rings and also the length of the chain belonging to the ester groups could be important for antileishmanial activity of these compounds. Most of these compounds exhibited low cytotoxicity against macrophages. Compounds 1 h, 2a, 2b and 2c revealed higher activity than glucantime while all compounds showed lower activity toward amphotericine B. Docking studies showed that the synthesized compounds were fit well in the PTR1 pocket. Compounds 1 h and 2c indicated the highest score docking among screened compounds in PTR1 enzyme | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Amastigotes | |
| 650 | 4 | |a Biginelli reaction | |
| 650 | 4 | |a Hantzsch reaction | |
| 650 | 4 | |a Molecular docking | |
| 650 | 4 | |a Promastigote | |
| 650 | 4 | |a Pteridine reductase 1 | |
| 650 | 7 | |a Antiprotozoal Agents |2 NLM | |
| 650 | 7 | |a Dihydropyridines |2 NLM | |
| 700 | 1 | |a Saberi, Sedigheh |e verfasserin |4 aut | |
| 700 | 1 | |a Menéndez, J Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Sepehri, Saghi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta parasitologica |d 1989 |g 67(2022), 1 vom: 19. März, Seite 255-266 |w (DE-627)NLM09254536X |x 1896-1851 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2022 |g number:1 |g day:19 |g month:03 |g pages:255-266 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11686-021-00457-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2022 |e 1 |b 19 |c 03 |h 255-266 | ||